All In MedTech

Device Trial Radar · NCT02979587

The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study

Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

86

Actual

Start

Jan 2017

Primary completion

Jul 17, 2020

Study completion Feb 2031

Sponsor

Lead sponsor
Medtronic Heart ValvesPublic (MDT)
Sponsor type
Industry
First posted
Dec 1, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to further evaluate the safety and effectiveness of the Harmony™ TPV system. The Pivotal/CAS phases of the study have transitioned into a post-approval study to confirm the long-term functionality of transcatheter implantation of the Medtronic Harmony TPV.

Conditions

  • Congenital Heart Disease
  • Tetrology of Fallot
  • RVOT Anomaly
  • Pulmonary Regurgitation

Interventions

  • Harmony TPV SystemDevice

    The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame. The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 Model HTPV254952 is not applicable for Continued Clinical Experience). The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom From Procedure- or Device-related Mortality at 30 Days.Time frame: 30 days
  2. Number of Participants With Acceptable Hemodynamic Function Composite at 6 MonthsTime frame: 6 months

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Ronald Regan UCLA Medical Center

    Los Angeles, California

  • Stanford University Medical Center

    Palo Alto, California

  • Yale University

    New Haven, Connecticut

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.